Clinical Trial

The Effect of Semaglutide on the Intestinal Flora in Obesity

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 7, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
For obese individuals, semaglutide treatment was adopted. By using multi-omics techniques such as fecal metagenomic sequencing and based on in vitro strain screening platforms, the effects and specific mechanisms of semaglutide on the intestinal flora of obese patients were clarified.
Trial Details
NCT Number NCT07323134
Lead Sponsor Beijing Chao Yang Hospital
Conditions Obesity
Enrollment 40 participants
Start Date 2026-02-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-07